Ponatinib

Pharmacological Classification

• Antineoplastic agent – Tyrosine Kinase Inhibitor (TKI)
• Specifically: BCR-ABL TKI (third-generation)
• Designed to inhibit native BCR-ABL and resistant mutants, including T315I, which other TKIs cannot target.

Mechanism of Action

• Inhibits BCR-ABL tyrosine kinase (oncogenic driver of chronic myeloid leukemia and some ALL).
• Active against wild-type BCR-ABL and TKI-resistant mutations (especially T315I).
• Also inhibits other kinases: VEGFR, FGFR, PDGFR, KIT, RET.
• This broad inhibition contributes to both efficacy and toxicity (notably vascular events, hypertension).

Indications (FDA/Health Canada approved)

• Adults with:
  • CML (Chronic Myeloid Leukemia) – chronic phase (CP), accelerated phase (AP), or blast phase (BP).
  • Ph+ ALL (Philadelphia chromosome–positive Acute Lymphoblastic Leukemia).
• Reserved for patients with:
  • T315I mutation OR
  • Disease resistant/intolerant to prior TKIs (imatinib, dasatinib, nilotinib, bosutinib).

Dosing

• Starting dose:
  • 45 mg orally once daily.
• Dose modifications:
  • Can reduce to 15–30 mg daily in responders (to mitigate vascular risk).
  • Adjust for toxicity (hypertension, pancreatitis, myelosuppression).
• Administration:
  • With or without food.
  • Tablets swallowed whole (no crushing).

Adverse Effects & Toxicities

Major Black Box Warning (BBW):

• Arterial and venous occlusive events (MI, stroke, PAD, venous thromboembolism). Can occur any time.
• Heart failure.
• Hepatotoxicity.

Other Common Toxicities:

• Hypertension (very common, often severe).
• Pancreatitis (elevated lipase/amylase).
• Myelosuppression (anemia, neutropenia, thrombocytopenia).
• Rash, dry skin.
• Arthralgia, abdominal pain.
• QT prolongation (rare but possible).

Monitoring

• Baseline & periodic:
  • CBC (myelosuppression).
  • Lipase/amylase (pancreatitis).
  • Liver function tests.
  • Blood pressure (strict control needed).
  • Cardiovascular risk factors (lipids, glucose).
  • EKG (QT interval if other risk factors).
• Assess for signs of vascular events (leg pain, chest pain, neuro symptoms).

Drug Interactions

• CYP3A4 substrate:
  • Strong CYP3A inhibitors (ketoconazole, clarithromycin) ↑ ponatinib levels → toxicity.
  • Strong CYP3A inducers (rifampin, phenytoin, St. John’s Wort) ↓ ponatinib levels → loss of efficacy.
• Antiplatelet/anticoagulant therapy: ↑ bleeding risk (but sometimes unavoidable in vascular disease).
• QT-prolonging drugs: additive risk.

Pharmacist Role

1. Patient Selection: Ensure indication (resistant CML/Ph+ ALL, T315I mutation).
2. Risk Mitigation:
   • Evaluate cardiovascular risk before starting.
   • Optimize control of BP, diabetes, hyperlipidemia.
   • Consider dose reduction once response achieved.
3. Monitoring:
   • CBC, LFTs, lipase, BP.
   • Patient education for vascular/ischemic symptoms.
4. Counseling:
   • Adherence (daily dosing critical).
   • Report chest pain, shortness of breath, leg pain, severe headache immediately.
   • Lifestyle advice: avoid smoking, manage hypertension and lipids.
5. Drug Interactions:
   • Avoid CYP3A4 modulators when possible.
   • Review concomitant meds for QT prolongation.

Summary

Ponatinib is a third-gen TKI used for resistant CML/Ph+ ALL (esp. T315I mutation). It is highly effective but limited by life-threatening vascular toxicity. Pharmacists are pivotal in patient selection, CV risk management, toxicity monitoring, and adherence support.